Table 2 –
Demographic characteristics of DSA-positive and DSA-negative recipients in IA group subjects with graft failure (n=13).
| DSA-positive recipients (n=6) | DSA-negative recipients (n=7) | p-value | |
|---|---|---|---|
| Female | 3 (50) | 4 (57.1) | 0.999 |
| Recipient Age at first transplant (years) | 43.7±6.9 | 45.8±13.8 | 0.733 |
| Duration of T1D (years) | 26.5±16.5 | 22.5±13.6 | 0.639 |
| Number of donors | 3±1 | 2±1 | 0.629 |
| HLA I mismatches d | 8 (7 – 9) | 8 (5 – 11) | 0.731 |
| HLA II mismatches d | 4 (2 – 5) | 2 (1 – 4) | 0.295 |
| Total IEQ/Kg body weight | 13 382 (12 956 – 29 593) | 8681 (5261 – 14 144) | 0.534 |
| Body weight (Kg) | 67.4±12.8 | 68.4±10.8 | 0.877 |
| Immunosuppression Edmonton Protocol,a n (%) | 6 (100) | 5 (71.4) | 0.462 |
| Immunosuppression T cell depletion,b n (%) | 0 | 2 (28.6) | 0.462 |
| Myfortic protocol,c n (%) | 2 (33.3) | 5 (71.4) | 0.286 |
| On Exenatide | 3 (50) | 4 (57.1) | 0.999 |
| Duration of graft function (years) | 3.3±1.5 | 3.1±2.1 | 0.851 |
| Total pregnancies | 0 (0 – 3; n=3) | 0 (0 – 3; n=4) | NA |
| CMV IgG-positivity | 4 (66.7) | 4 (57.1) | 0.999 |
| Autoantibody positivity # | 4 (66.7) | 3 (60.0) | 0.999 |
Abbreviations: CMV, cytomegalovirus; DSA, donor-specific anti-HLA antibodies; IA, islet transplantation alone;
IEQ, islet equivalents; IgG, immunoglobulin G; T1D, type 1 diabetes.
a
The Edmonton Protocol for islet transplantation consists of a glucocorticoid-free immunosuppressive regimen (sirolimus, tacrolimus, daclizumab).
b
Alemtuzumab or thymoglobulin.
c
Myfortic=mycophenolic acid.
(#)
Autoantibody assessment was performed in 12 out of 13 subjects.
d
Maximum number of mismatches per donor = 4.